OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Facon on the Implications of Isatuximab Plus VRd in Transplant-Ineligible Newly Diagnosed Myeloma

July 25th 2024

Thierry Facon, MD, discusses clinical implications from the phase 3 IMROZ trial

Dr Morgans on the Relationship Between PSA Levels and Radiographic Progression in nmCRPC

July 25th 2024

Alicia Morgans, MD, MPH, discusses key data from the follow-up analysis of the phase 3 ARAMIS trial in nonmetastatic castration-resistant prostate cancer.

Dr Posner on the Mechanism of Action of Danivatirsen in HNSCC

July 25th 2024

Marshall Posner, MD, discusses the mechanism of action of danvatirsen in recurrent and/or metastatic head and neck squamous cell carcinoma.

Dr Saliby on the Correlation Between Intermediate End Points and OS in Metastatic RCC

July 25th 2024

Renee Saliby, MD, MSc discusses the relationship between intermediate end points and overall survival in metastatic renal cell carcinoma.

Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes

July 25th 2024

Julia Rotow, MD, discusses the importance of comprehensive biomarker testing for all patients with NSCLC.

Dr Sabari on Barriers to Biomarker Testing in NSCLC

July 25th 2024

Joshua K. Sabari, MD, discusses barriers to biomarker testing in patients with non–small cell lung cancer.

Dr Thompson on Trials Evaluating De-Escalated Treatment in Early-Stage Breast Cancer

July 24th 2024

Alastair Thompson, BSc, MBChB, MD, FRCS, discusses ongoing trials evaluating de-escalated treatment in early-stage breast cancer.

Dr Landgren on the Management of Newly Diagnosed Multiple Myeloma Treatment

July 24th 2024

C. Ola Landgren, MD, PhD, discusses standard treatment approaches and the advantages of quadruplet regimens in newly diagnosed multiple myeloma.

Dr Tolaney on the Development of Mutation-Selective PI3K Inhibitors in Breast Cancer

July 24th 2024

Sara M. Tolaney, MD, MPH, discusses the ongoing development of mutation-selective PI3K inhibitors in PI3K-mutant metastatic breast cancer.

Dr Brufsky on the Unique Design of the Allogeneic SV-BR-1-GM Vaccine in Metastatic Breast Cancer

July 24th 2024

Adam M. Brufsky, MD, PhD, FACP, discusses the unique design of the allogeneic GM-CSF–secreting breast cancer vaccine SV-BR-1-GM.

Dr Watts on the Investigation of INCB057643 in Advanced Myelofibrosis and MPN

July 24th 2024

Justin M. Watts, MD, discusses the design and purpose of a phase 1 trial evaluating INCB057643 in myelofibrosis and other advanced myeloid neoplasms.

Dr Tolaney on the Potential Role for Biomarkers in Early-Stage HER2+ Breast Cancer

July 24th 2024

Sara M. Tolaney, MD, MPH, discusses the potential role for biomarkers in guiding treatment decisions in early-stage HER2-positive breast cancer.

Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC

July 24th 2024

Leah Backhus, MD, MPH, FACS, discusses the evolving definition of surgical resectability in patients with borderline resectable NSCLC.

Dr Herbst on the Importance of Multidisciplinary Collaboration in NSCLC

July 24th 2024

Roy S. Herbst, MD, PhD, discusses the importance of consulting a multidisciplinary tumor board when making treatment decisions for patients with NSCLC.

Dr Shah on Research to Minimize Surgical Intervention in Locoregional Breast Cancer

July 23rd 2024

Chirag Shah, MD, discusses ongoing clinical trials aiming to minimize surgical intervention in locoregional breast cancer.

Dr Mouabbi on Clinical Trials for Invasive Lobular Breast Cancer

July 23rd 2024

Jason A. Mouabbi, MD, discusses clinical trials aimed at expanding the treatment paradigm for invasive lobular breast cancer.

Dr Li on Unmet Needs in High-Risk MIBC

July 23rd 2024

Roger Li, MD, discusses persisting unmet needs in high-risk, muscle-invasive bladder cancer.

Dr Franses on the Need for Prospective Data in Second-Line HCC and Beyond

July 23rd 2024

Joseph Franses, MD, PhD, discusses the need for more prospective data in the second-line setting and beyond for patients with hepatocellular carcinoma.

Dr Rini on the Background of a Biomarker Analysis of KEYNOTE-426 in RCC

July 23rd 2024

Brian I. Rini, MD, FASCO, discusses an analysis of clustering from the KEYNOTE-426 study in patients with advanced renal cell carcinoma.

Dr Grimm on the Rationale for Conducting a Post-Hoc Analysis of ARASENS in mHSPC

July 23rd 2024

Marc-Oliver Grimm, MD, discusses a post-hoc analysis of the ARASENS trial in metastatic hormone-sensitive prostate cancer.